Inaktiver Wert

pSivida Corp. Aktie Nasdaq

Aktien

Dauer

Zeitraum

Stil

PSivida : Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle	09.08.16
PSivida : Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve	14.07.16
PSivida : Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe	02.05.16
PSivida : Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs	28.09.15
PSivida : CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015	14.09.15

Sektor

	% 1. Jan.	Kap.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103 Mrd.
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28 Mrd.
ARGENX SE	+1.69%	22.15 Mrd.
BIONTECH SE	-17.37%	21.02 Mrd.
GENMAB A/S	-9.30%	18.15 Mrd.
WUXI APPTEC CO., LTD.	-41.01%	16.74 Mrd.
BEIGENE, LTD.	-14.85%	16.05 Mrd.
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68 Mrd.
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17 Mrd.